Home › Calculator › OCUL Dividend Calculator 2026
OCUL Dividend DRIP Calculator 2026
20.36% YieldHealthcareOcular Therapeutix, Inc. · NASDAQ
Price: $9.82 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When OCUL pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your OCUL snowball 📈
$10,000 in OCUL → $64.5K in 10 years · $1,200.99/month
About Ocular Therapeutix, Inc. (OCUL) — Dividend Analysis 2026
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Compare OCUL with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full OCUL DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open OCUL position with:
🌍 OCUL Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold OCUL.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 20.36% | 17.56% | $2,036 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 17.31% | 14.51% | $1,731 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 16.29% | 13.49% | $1,629 / yr |
| 🇬🇧 UK ISA | 0% | 20.36% | 17.56% | $2,036 / yr |
| 🇬🇧 UK Taxable | 8.75% | 18.58% | 15.78% | $1,858 / yr |
| 🇨🇦 TFSA | 0% | 20.36% | 17.56% | $2,036 / yr |
| 🇨🇦 CA Taxable | 25% | 15.27% | 12.47% | $1,527 / yr |
| 🇦🇺 Super (pension) | 15% | 17.31% | 14.51% | $1,731 / yr |
| 🇦🇺 AU Taxable | 30% | 14.25% | 11.45% | $1,425 / yr |
| 🇩🇪 DE Taxable | 26.375% | 14.99% | 12.19% | $1,499 / yr |
| 🇫🇷 FR Taxable | 30% | 14.25% | 11.45% | $1,425 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 OCUL Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 OCUL Dividend Payment Schedule
OCUL pays quarterly — 4 times per year. Next ex-div: TBD.
📊 OCUL vs Healthcare Benchmarks
How OCUL compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for OCUL sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ OCUL Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| G-Gift | 2026-06-16 | 50,092 | — | — | ||
| G-Gift | 2026-06-16 | 50,092 | — | — | ||
| A-Award | 2026-06-10 | 14,000 | — | — | ||
| A-Award | 2026-06-10 | 44,000 | $8.74 | $384.6K | ||
| A-Award | 2026-06-10 | 14,000 | — | — | ||
| A-Award | 2026-06-10 | 44,000 | $8.74 | $384.6K | ||
| A-Award | 2026-06-10 | 15,441 | — | — | ||
| A-Award | 2026-06-10 | 14,024 | $8.74 | $122.6K | ||
| A-Award | 2026-06-10 | 14,000 | — | — | ||
| A-Award | 2026-06-10 | 44,000 | $8.74 | $384.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the OCUL dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ocular Therapeutix, Inc. (OCUL) is currently trading at $9.82, 51% below its 52-week high. The current dividend yield is 20.36% based on an annual payout of $2.00 per share.
OCUL (Ocular Therapeutix, Inc.) — 20.36% Dividend Yield Analysis
Ocular Therapeutix, Inc. (OCUL) is a healthcare stock currently trading at $9.82 with a dividend yield of 20.36%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (20.36%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.